|
FDA’s Lack of Policy on New EU Directive Causes Shortage Concerns
The FDA’s lack of a policy or guidance to help API manufacturers deal with a new European directive on falsified medicines is causing concern among manufacturers about lost sales and drug shortages in Europe, an expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives